COVID-19
The company’s lead candidate, INNA-051, is an innate immune agonist that directly stimulates the host’s natural immune defense system.
The new data shows REGEN-COV reduced the risk of death in hospitalized patients unable to mount their own immune response by 20%.
Repurposed drugs became the front-line defense against COVID-19 within a few months of the pandemic’s emergence. Now bucillamine, currently in Phase III trials in the U.S., may be poised to join them.
A recent study conducted by Public Health England found that the available vaccines were “highly effective” at preventing hospitalization after two doses.
Please check out the biopharma industry’s COVID-19 stories that are trending for June 15, 2021.
The failure marks a setback in the hunt for means other than vaccines to provide protection against the novel coronavirus and its variants.
A sense of urgency, powerful science, relentless ingenuity, hope and trust drove the development of Pfizer and BioNTech’s mRNA vaccine during the height of the COVID-19 pandemic. As the crisis appears to lessen, Pfizer is preparing for the next pandemic.
Investigators from the Cleveland Clinic assessed possible relationships between COVID-19 and neuroinflammation and brain microvascular injury – two hallmarks of AD.
The study also found the vaccine was 100% effective at preventing moderate and severe disease.
The EMA identified a rare blood condition, capillary leak syndrome, as a potential side effect of AstraZeneca’s Vaxzevria.
PRESS RELEASES